AstraZeneca PLC (AZN)
75.38
+4.18
(+5.87%)
USD |
NASDAQ |
Apr 25, 11:34
AstraZeneca Enterprise Value: 242.40B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 242.40B |
| April 23, 2024 | 241.32B |
| April 22, 2024 | 239.09B |
| April 19, 2024 | 234.19B |
| April 18, 2024 | 233.60B |
| April 17, 2024 | 234.13B |
| April 16, 2024 | 233.30B |
| April 15, 2024 | 234.75B |
| April 12, 2024 | 235.37B |
| April 11, 2024 | 236.98B |
| April 10, 2024 | 232.82B |
| April 09, 2024 | 233.75B |
| April 08, 2024 | 231.55B |
| April 05, 2024 | 230.78B |
| April 04, 2024 | 230.44B |
| April 03, 2024 | 228.79B |
| April 02, 2024 | 229.38B |
| April 01, 2024 | 230.16B |
| March 28, 2024 | 231.71B |
| March 27, 2024 | 233.29B |
| March 26, 2024 | 227.31B |
| March 25, 2024 | 225.85B |
| March 22, 2024 | 227.09B |
| March 21, 2024 | 226.87B |
| March 20, 2024 | 225.44B |
| Date | Value |
|---|---|
| March 19, 2024 | 225.85B |
| March 18, 2024 | 225.82B |
| March 15, 2024 | 227.24B |
| March 14, 2024 | 229.51B |
| March 13, 2024 | 231.18B |
| March 12, 2024 | 230.62B |
| March 11, 2024 | 231.46B |
| March 08, 2024 | 227.83B |
| March 07, 2024 | 226.87B |
| March 06, 2024 | 224.02B |
| March 05, 2024 | 222.59B |
| March 04, 2024 | 222.53B |
| March 01, 2024 | 221.94B |
| February 29, 2024 | 220.58B |
| February 28, 2024 | 224.27B |
| February 27, 2024 | 227.31B |
| February 26, 2024 | 226.06B |
| February 23, 2024 | 225.75B |
| February 22, 2024 | 220.48B |
| February 21, 2024 | 223.46B |
| February 20, 2024 | 223.31B |
| February 16, 2024 | 220.92B |
| February 15, 2024 | 216.48B |
| February 14, 2024 | 212.83B |
| February 13, 2024 | 210.87B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
111.98B
Minimum
Mar 16 2020
259.09B
Maximum
Apr 24 2023
187.52B
Average
194.78B
Median
Dec 08 2021
Enterprise Value Benchmarks
| GSK PLC | 97.83B |
| Amgen Inc | 199.98B |
| Sanofi SA | 124.93B |
| Viking Therapeutics Inc | 6.177B |
| Fusion Pharmaceuticals Inc | 1.614B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 960.00M |
| Revenue (Quarterly) | 12.02B |
| Total Expenses (Quarterly) | 10.02B |
| EPS Diluted (Quarterly) | 0.31 |
| Gross Profit Margin (Quarterly) | 80.81% |
| Profit Margin (Quarterly) | 7.98% |
| Earnings Yield | 2.54% |
| Operating Earnings Yield | 3.70% |
| Normalized Earnings Yield | 2.709 |